Italian multicenter study, will enroll \~566 pts with oligometastatic hormone sensitive prostate cancer who are candidates to receive treatment with apalutamide.
After 6 months from the start of treatment, patients will be randomized to receive local treatment based on the investigator's choice ( either one between primary radiotherapy or cytoreductive prostatectomy), in addition to apalutamide, or to continue just with medical therapy.
Age > 18
Histologically confirmed diagnosis of prostate adenocarcinoma
Metastatic disease documented by ≥1 bone lesion with Technetium 99m (99mTc) bone scan. Individuals with only one bone lesion should have confirmation of that lesion on CT or MRI.
Eastern Cooperative Oncology Group Performance Status (ECOG PS) Grade ≤ 2
Pathologic findings consistent with small cell, ductal, or neuroendocrine prostate cancer.
Known brain metastases.
Lymph node metastases only.
Visceral metastases.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Lead sponsor
ASST Santi Paolo e Carlo
Collaborator
European Institute of Oncology
Collaborator